UNLABELLED: Insulin-like growth factor 1 (IGF-1) and its IGF-1 receptor (IGF-1R) belong to an important biological system that is involved in the regulation of normal growth, but that has also been recognized as playing a role in cancer. IGF-1R antagonists could be interesting for the testing of their potential antiproliferative properties as an alternative to IGF-1R tyrosine-kinase inhibitors or anti-IGF-1R monoclonal antibodies. In this study, we were inspired by the successful development of insulin dimers capable of antagonizing insulin effects on the insulin receptor (IR) by simultaneous binding to two separated binding sites and by blocking structural rearrangement of the IR. We designed and produced in Escherichia coli three different IGF-1 dimers in which IGF-1 monomers are interlinked through their N- and C-termini, with linkers having 8, 15 or 25 amino acids. We found that the recombinant products were susceptible to the formation of misfolded or reduced variants, but that some of them were able to bind IGF-1R in low nanomolar affinities and all of them activate IGF-1R proportionally to their binding affinities. Overall, our work can be considered as a pilot study that, although it did not lead to the discovery of new IGF-1R antagonists, explored the possibility of recombinant production of IGF-1 dimers and led to the preparation of active compounds. This work could inspire further studies dealing, for example, with the preparation of IGF-1 conjugates with specific proteins for the study of the hormone and its receptor or for therapeutic applications. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s10989-023-10499-1.

Department of Biochemistry Faculty of Science Charles University 12840 Prague 2 Czech Republic

Institute of Organic Chemistry and Biochemistry Czech Academy of Sciences Flemingovo nám 2 116 10 Prague 6 Czech Republic

Present Address Department of Biology University of York Wentworth Way York YO10 5DD UK

Zobrazit více v PubMed

Barton ER. Viral expression of insulin-like growth factor-I isoforms promotes different responses in skeletal muscle. J Appl Physiol. 2006;100:1778–1784. doi: 10.1152/japplphysiol.01405.2005. PubMed DOI

Barton ER, Morris L, Musaro A, Rosenthal N, Sweeney HL. Muscle-specific expression of insulin-like growth factor I counters muscle decline in mdx mice. J Cell Biol. 2002;157:137–147. doi: 10.1083/jcb.200108071. PubMed DOI PMC

Baserga R. The decline and fall of the IGF-I receptor. J Cell Physiol. 2013;228:675–679. doi: 10.1002/jcp.24217. PubMed DOI

Belfiore A, Malaguarnera R, Vella V, et al. Insulin receptor isoforms in physiology and disease: an updated view. Endocr Rev. 2017;38:379–431. doi: 10.1210/er.2017-00073. PubMed DOI PMC

Brandt SJ, Mayer JP, Ford J, Gelfanov VM, DiMarchi RD. Controlled intramolecular antagonism as a regulator of insulin receptor maximal activity. Peptides. 2018;100:18–23. doi: 10.1016/j.peptides.2017.11.022. PubMed DOI

Christoffersen CT, Bornfeldt KE, Rotella CM, et al. Negative cooperativity in the insulin-like growth factor-I receptor and a chimeric IGF-I/insulin receptor. Endocrinology. 1994;135:472–475. doi: 10.1210/endo.135.1.8013387. PubMed DOI

Clemmons DR. Role of IGF-I in skeletal muscle mass maintenance. Trends Endocrinol Metab. 2009;20:349–356. doi: 10.1016/j.tem.2009.04.002. PubMed DOI

Croll TI, Smith BJ, Margetts MB, et al. Higher-resolution structure of the human insulin receptor ectodomain: multi-modal inclusion of the insert domain. Structure. 2016;24:469–476. doi: 10.1016/j.str.2015.12.014. PubMed DOI PMC

De Meyts P. The structural basis of insulin and insulin-like growth factor-I receptor binding and negative co-operativity, and its relevance to mitogenic versus metabolic signalling. Diabetologia. 1994;37(Suppl 2):S135–S148. doi: 10.1007/BF00400837. PubMed DOI

De Meyts P, Roth J, Neville DM, Jr, Gavin JR, III, Lesniak MA. Insulin interactions with its receptors: experimental evidence for negative cooperativity. Biochem Biophys Res Commun. 1973;55:154–161. doi: 10.1016/s0006-291x(73)80072-5. PubMed DOI

Denley A, Cosgrove LJ, Booker GW, Wallace JC, Forbes BE. Molecular interactions of the IGF system. Cytokine Growth Factor Rev. 2005;16:421–439. doi: 10.1016/j.cytogfr.2005.04.004. PubMed DOI

Fettig LM, Yee D. Advances in insulin-like growth factor biology and -directed cancer therapeutics. Adv Cancer Res. 2020;147:229–257. doi: 10.1016/bs.acr.2020.04.005. PubMed DOI PMC

Forbes BE, Blyth AJ, Wit JM. Disorders of IGFs and IGF-1R signaling pathways. Mol Cell Endocrinol. 2020;518:111035. doi: 10.1016/j.mce.2020.111035. PubMed DOI

Fujita M, Ieguchi K, Cedano-Prieto DM, et al. An integrin binding-defective mutant of insulin-like growth factor-1 (R36E/R37E IGF1) acts as a dominant-negative antagonist of the IGF1 receptor (IGF1R) and suppresses tumorigenesis but still binds to IGF1R. J Biol Chem. 2013;288:19593–19603. doi: 10.1074/jbc.M113.470872. PubMed DOI PMC

Gill R, Verma C, Wallach B, et al. Modelling of the disulphide-swapped isomer of human insulin-like growth factor-1: implications for receptor binding. Protein Eng. 1999;12:297–303. doi: 10.1093/protein/12.4.297. PubMed DOI

Gutmann T, Kim KH, Grzybek M, Walz T, Coskun U. Visualization of ligand-induced transmembrane signaling in the full-length human insulin receptor. J Cell Biol. 2018;217:1643–1649. doi: 10.1083/jcb.201711047. PubMed DOI PMC

Gutmann T, Schaeffer IB, et al. Cryo-EM structure of the complete and ligand-saturated insulin receptor ectodomain. J Cell Biol. 2020;219:1–16. doi: 10.1101/679233. PubMed DOI PMC

Hexnerova R, Krizkova K, Fabry M, et al. Probing receptor specificity by sampling the conformational Space of the insulin-like growth factor II C-domain. J Biol Chem. 2016;291:21234–21245. doi: 10.1074/jbc.M116.741041. PubMed DOI PMC

Hober S, Forsberg G, Palm G, Hartmanis M, Nilsson B. Disulfide exchange folding of insulin-like growth factor-I. Biochemistry. 1992;31:1749–1756. doi: 10.1021/bi00121a024. PubMed DOI

Jacobson MP, Pincus DL, Rapp CS, et al. A hierarchical approach to all-atom protein loop prediction. Proteins. 2004;55:351–367. doi: 10.1002/prot.10613. PubMed DOI

Kiselyov VV, Versteyhe S, Gauguin L, De Meyts P. Harmonic oscillator model of the insulin and IGF1 receptors’ allosteric binding and activation. Mol Syst Biol. 2009;5:243. doi: 10.1038/msb.2008.78. PubMed DOI PMC

Lawrence MC. Understanding insulin and its receptor from their three-dimensional structures. Mol Metab. 2021;52:101255. doi: 10.1016/j.molmet.2021.101255. PubMed DOI PMC

Lemmon MA, Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell. 2010;141:1117–1134. doi: 10.1016/j.cell.2010.06.011. PubMed DOI PMC

LeRoith D, Roberts CT. The insulin-like growth factor system and cancer. Cancer Lett. 2003;195:127–137. doi: 10.1016/s0304-3835(03)00159-9. PubMed DOI

LeRoith D, Holly JMP, Forbes BE. Insulin-like growth factors: ligands, binding proteins, and receptors. Mol Metab. 2021;52:101245. doi: 10.1016/j.molmet.2021.101245. PubMed DOI PMC

Levitzki A, Koshland DE., Jr Negative cooperativity in regulatory enzymes. Proc Natl Acad Sci USA. 1969;62:1121–1128. doi: 10.1073/pnas.62.4.1121. PubMed DOI PMC

Li J, Choi E, Yu H, Bai XC. Structural basis of the activation of type 1 insulin-like growth factor receptor. Nat Commun. 2019;10:4567. doi: 10.1038/s41467-019-12564-0. PubMed DOI PMC

Li J, Park J, Mayer JP, et al. Synergistic activation of the insulin receptor via two distinct sites. Nat Struct Mol Biol. 2022;29:357–368. doi: 10.1038/s41594-022-00750-6. PubMed DOI PMC

Lin J, Selicharova I, Mitrova K, et al. Targeting the insulin receptor with hormone and peptide dimers. J Pept Sci. 2022 doi: 10.1002/psc.3461. PubMed DOI

Lynch GS, Cuffe SA, Plant DR, Gregorevic P. IGF-I treatment improves the functional properties of fast- and slow-twitch skeletal muscles from dystrophic mice. Neuromuscul Disord. 2001;11:260–268. doi: 10.1016/S0960-8966(00)00192-9. PubMed DOI

Machackova K, Collinsova M, Chrudinova M, et al. Insulin-like growth factor 1 Analogs clicked in the C domain: chemical synthesis and biological activities. J Med Chem. 2017;60:10105–10117. doi: 10.1021/acs.jmedchem.7b01331. PubMed DOI

Machackova K, Mlcochova K, Potalitsyn P, et al. Mutations at hypothetical binding site 2 in insulin and insulin-like growth factors 1 and 2 result in receptor- and hormone-specific responses. J Biol Chem. 2019;294:17371–17382. doi: 10.1074/jbc.RA119.010072. PubMed DOI PMC

McKern NM, Lawrence MC, Streltsov VA, et al. Structure of the insulin receptor ectodomain reveals a folded-over conformation. Nature. 2006;443:218–221. doi: 10.1038/nature05106. PubMed DOI

Micsonai A, Wien F, Bulyaki E, et al. BeStSel: a web server for accurate protein secondary structure prediction and fold recognition from the circular dichroism spectra. Nucleic Acids Res. 2018;46:W315–W322. doi: 10.1093/nar/gky497. PubMed DOI PMC

Miller JA, Narhi LO, Hua QX, et al. Oxidative refolding of insulin-like growth factor-I yields 2 products of similar thermodynamic stability—a bifurcating protein-folding pathway. Biochemistry. 1993;32:5203–5213. doi: 10.1021/bi00070a032. PubMed DOI

Moreau F, Kirk NS, Zhang F, et al. Interaction of a viral insulin-like peptide with the IGF-1 receptor produces a natural antagonist. Nat Commun. 2022;13:6700. doi: 10.1038/s41467-022-34391-6. PubMed DOI PMC

Nagao H, Cai W, Wewer Albrechtsen NJ, et al. Distinct signaling by insulin and IGF-1 receptors and their extra- and intracellular domains. Proc Natl Acad Sci USA. 2021 doi: 10.1073/pnas.2019474118. PubMed DOI PMC

Nielsen J, Brandt J, Boesen T, et al. Structural investigations of full-length insulin receptor dynamics and signalling. J Mol Biol. 2022;434:167458. doi: 10.1016/j.jmb.2022.167458. PubMed DOI

Pillutla R, Brissette R, Blume AJ, Schäffer L, Brandt J, Goldstein NI, Spetzler J, Østergaard S, Hansen PH (2011) Insulin and IGF-1 receptor agonists and antagonists. US Patent 2011/0124556 A1

Pissarnitski DA, Kekec A, Yan L, et al. Discovery of insulin receptor partial Agonists MK-5160 and MK-1092 as novel basal insulins with potential to Improve Therapeutic Index. J Med Chem. 2022;65:5593–5605. doi: 10.1021/acs.jmedchem.1c02073. PubMed DOI

Saegusa J, Yamaji S, Ieguchi K, et al. The direct binding of insulin-like growth factor-1 (IGF-1) to integrin alpha v beta 3 is involved in IGF-1 signaling. J Biol Chem. 2009;284:24106–24114. doi: 10.1074/jbc.M109.013201. PubMed DOI PMC

Saltiel AR. Insulin signaling in health and disease. J Clin Invest. 2021;131:e142241. doi: 10.1172/JCI142241. PubMed DOI PMC

Samani AA, Yakar S, LeRoith D, Brodt P. The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr Rev. 2007;28:20–47. doi: 10.1210/er.2006-0001. PubMed DOI

Schrödinger Release (2023)-1: Desmond Molecular Dynamics System, D. E. Shaw Research, New York, NY, 2021. Maestro-Desmond Interoperability Tools, Schrödinger. https://www.schrodinger.com

Schuttler A, Brandenburg D. Preparation and properties of covalently linked insulin dimers. Hoppe-Seylers Z Physiol Chem. 1982;363:317–330. doi: 10.1515/bchm2.1982.363.1.3. PubMed DOI

Sohma Y, Pentelute BL, Whittaker J, et al. Comparative properties of insulin-like growth factor 1 (IGF-1) and [Gly7D-Ala]IGF-1 prepared by total chemical synthesis. Angew Chem Int Ed. 2008;47:1102–1106. doi: 10.1002/anie.200703521. PubMed DOI

Sohma Y, Hua QX, Liu M, et al. Contribution of Residue B5 to the folding and function of insulin and IGF-I. Constraints and fine tuning in the evolution of a protein family. J Biol Chem. 2010;285:5040–5055. doi: 10.1074/jbc.M109.062992. PubMed DOI PMC

Tatnell MA, Jones RH, Willey KP, Schuttler A, Brandenburg D. Evidence concerning the mechanism of insulin-receptor interaction and the structure of the insulin-receptor from biological properties of covalently linked insulin dimers. Biochem J. 1983;216:687–694. doi: 10.1042/bj2160687. PubMed DOI PMC

Uchikawa E, Choi E, Shang GJ, Yu HT, Bai XC. Activation mechanism of the insulin receptor revealed by cryo-EM structure of the fully liganded receptor-ligand complex. eLife. 2019;8:e48630. doi: 10.7554/eLife.48630. PubMed DOI PMC

Weiland M, Brandenburg C, Brandenburg D, Joost HG. Antagonistic effects of a covalently dimerized insulin derivative on insulin-receptors in 3T3-L1 adipocytes. Proc Natl Acad Sci USA. 1990;87:1154–1158. doi: 10.1073/pnas.87.3.1154. PubMed DOI PMC

Weis F, Menting JG, Margetts MB, et al. The signalling conformation of the insulin receptor ectodomain. Nat Commun. 2018;9:4420. doi: 10.1038/s41467-018-06826-6. PubMed DOI PMC

Wu M, Carballo-Jane E, Zhou H, et al. Functionally selective signaling and broad metabolic benefits by novel insulin receptor partial agonists. Nat Commun. 2022;13:942. doi: 10.1038/s41467-022-28561-9. PubMed DOI PMC

Xiong X, Blakely A, Kim JH, et al. Symmetric and asymmetric receptor conformation continuum induced by a new insulin. Nat Chem Biol. 2022;18:511–519. doi: 10.1038/s41589-022-00981-0. PubMed DOI PMC

Xu Y, Kong GK, Menting JG, et al. How ligand binds to the type 1 insulin-like growth factor receptor. Nat Commun. 2018;9:821. doi: 10.1038/s41467-018-03219-7. PubMed DOI PMC

Zhang F, Altindis E, Kahn CR, DiMarchi RD, Gelfanov V. A viral insulin-like peptide is a natural competitive antagonist of the human IGF-1 receptor. Mol Metab. 2021;53:101316. doi: 10.1016/j.molmet.2021.101316. PubMed DOI PMC